Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Intel Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Intel Corp trades at $106.68 (market cap $552.06B). The key difference: Intel Corp is far larger — about 13.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | INTC | |
|---|---|---|
Market Cap | $39.89B | $552.06B |
Sector | Health | Technology |
52-Week High | $491.22 | $140.94 |
52-Week Low | $278.09 | $19.31 |
Enterprise Value | $38.15B | $564.30B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Intel (INTC) trades at $109.84, down 2.4% on the day, with a bearish technical signal but recent earnings beats. The stock shows mixed fundamentals with a high P/E of 904.17 and negative net margin of -5.9%, though operating cash flow improved to $9.70B in 2025. News highlights government support and turnaround progress, with consensus price target at $99.70.
Outlook remains cautious due to profitability challenges and competitive pressures, but long-term growth potential exists from AI and foundry expansions. Key risks include execution on capital investments and market share loss to AMD. Analyst sentiment is mixed with 36.9% buy ratings, suggesting patience for turnaround results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
